News >

Schwartzberg Highlights Existing and Emerging Targets in NSCLC

Angelica Welch
Published: Tuesday, Mar 06, 2018

Lee S. Schwartzberg,

Lee S. Schwartzberg, MD, FACP
Next-generation sequencing (NGS) has allowed clinicians to prescribe treatment for their patients based on individual genomic abnormalities and Lee Schwartzberg, MD, emphasizes that undergoing such testing at the beginning of a cancer diagnosis is critical to optimizing patient outcomes.

In an interview during the meeting, Schwartzberg, executive director, West Cancer Center, chief, Division of Hematology/Oncology, University of Tennessee Health Science Center, discussed the importance of NGS and the state of biomarker development in the management of patients with NSCLC.

OncLive: Please provide an overview of your presentation on biomarkers in NSCLC.

Schwartzberg: Biomarkers are critical in the management of NSCLC today because we have drugs specifically designed for a large number of subgroups. There are many patients with NSCLC who have a driver mutation, and many of them are actionable—EGFR, ALK, ROS, and BRAF, for example. We also have biomarkers that are in development, and are already clinically useful to determine the best candidates for immuno-oncology drugs, such as PD-1/PD-L1 antibodies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication